ERBB2 and breast carcinoma: The pilot imaging trial of 89Z-trastuzumab-PET included 14 patients with HER2-positive breast cancer, and demonstrated excellent tumor uptake of the tracer on delayed imaging (approximately 5 days post injection) and visualization of nearly all known metastases as well as several occult metastases [116].